Targeted Delivery of Nano-Therapeutics for Major Disorders of the Central Nervous System

被引：150

作者：

Gao, Huile ^{[1
,2
]}

Pang, Zhiqing ^{[1
,2
]}

Jiang, Xinguo ^{[1
,2
]}

机构：

[1] Fudan Univ, Key Lab Smart Drug Delivery, Minist Educ, Shanghai 201203, Peoples R China

[2] Fudan Univ, Dept Pharmaceut Sci, Sch Pharm, Shanghai 201203, Peoples R China

来源：

PHARMACEUTICAL RESEARCH | 2013年 / 30卷 / 10期

基金：

中国国家自然科学基金;

关键词：

brain tumor; central nervous system; cerebrovascular disease; neurodegenerative disorder; targeted delivery; BLOOD-BRAIN-BARRIER; PEG-PLGA NANOPARTICLES; FIBROBLAST-GROWTH-FACTOR; A-BETA ANTIBODY; DRUG-DELIVERY; IN-VITRO; ENABLES NEUROPROTECTION; NEUROTROPHIC FACTOR; PLA NANOPARTICLES; PARKINSON DISEASE;

D O I：

10.1007/s11095-013-1122-4

中图分类号：

O6 [化学];

学科分类号：

070301 [无机化学];

摘要：

Major central nervous system (CNS) disorders, including brain tumors, Alzheimer's disease, Parkinson's disease, and stroke, are significant threats to human health. Although impressive advances in the treatment of CNS disorders have been made during the past few decades, the success rates are still moderate if not poor. The blood-brain barrier (BBB) hampers the access of systemically administered drugs to the brain. The development of nanotechnology provides powerful tools to deliver therapeutics to target sites. Anchoring them with specific ligands can endow the nano-therapeutics with the appropriate properties to circumvent the BBB. In this review, the potential nanotechnology-based targeted drug delivery strategies for different CNS disorders are described. The limitations and future directions of brain-targeted delivery systems are also discussed.

引用

页码：2485 / 2498

页数：14

共 150 条

[1]

The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease [J].